Fischer L. von Weikersthal - Gesundheitszentrum St Marien

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 7 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Analyse zweier prospektiver klinischer Studien der Arbeitsgemeinschaft Internistische Onkologie mit der "Burden of Therapy" (BOTh (R) TM) Methode - einem neuen Instrument zur Evaluation unerwunschter Ereignisse beim metastasierten Pankreaskarzinom

K. Dorman, V. Heinemann, R. J. Snijder, D. T. Waldschmidt, J. Freiberg-Richter, J. T. Siveke,Fischer L. Von Weikersthal, A. Reinacher-Schick, M. Schenk, J. Mayerle, K. Caca, M. Stahl,

ONCOLOGY RESEARCH AND TREATMENTno. SUPPL 2 (2022): 295-295

引用0浏览0引用

Final analysis of the non-interventional study (NIS) "StepUp" assessing dosing schedules of oral vinorelbine in patients with advanced non-small cell lung cancer (NSCLC) or metastatic breast cancer (MBC) in clinical routine in Germany and Austria

F. Roitner, S. Angermeier,M. de Wit, M. Groschek,Fischer L. von Weikersthal, O. Tome,E. Petru,H-J Strittmatter,M. Rauter, J. Bischoff,W. J. Randerath,C. Schem,

ONCOLOGY RESEARCH AND TREATMENT（2018）

引用0浏览0引用

Randomized Phase Iii Study Of Fluoropyrimidine (Fp) Plus Bevacizumab (Bev) Vs. Fp Plus Irinotecan (Iri) And Bev As First-Line Therapy For Metastatic Colorectal Cancer (Mcrc): German Aio Krk0110 (Ml22011) - Study

D. P. Modest,Fischer L. Von Weikersthal,T. Decker,U. Vehling-Kaiser, J. Uhlig,M. Schenk, J. Freiberg-Richter, B. Peuser, C. Denzlinger,Peveling Genannt C. Reddemann,U. Graeven, G. Schuch,

ANNALS OF ONCOLOGY（2017）

引用3浏览0WOS引用

Subcutaneous rituximab in patients with DLBCL and follicular NHL - First interim results from the non-interventional study MabSCale

J. Duerig, I Azeh, K. Blumenstengel,A. Gerhardt,M. Haenel, G. Hapke, M. Hensel, J. Hessling, H. -G Hoeffkes, H. -J Hurtz, M. Ritter, P. Staib,

ONCOLOGY RESEARCH AND TREATMENTno. SUPnan (2016): 156-156

引用0浏览0引用

Impact of hand-foot skin reaction (HFS) on treatment efficacy in patients (pts) receiving capecitabine/gemcitabine plus erlotinib for pancreatic cancer (PC): a subgroup analysis from the AIO-PK0104 randomized, cross-over phase III trial in advanced PC

M. Haas, S. Boeck, R. P. Laubender, D. P. Modest, U. Vehling-Kaiser, D. Waldschmidt, E. Kettner, A. Maerten, C. Winkelmann,S. Klein, G. Kojouharoff,T. C. Gauler,

ONKOLOGIE（2012）

引用0浏览0引用

Phase III randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) followed by sunitinib (SU) versus sunitinib followed by sorafenib in patients with advanced/metastatic renal cell carcinoma without prior systemic therapy (SWITCH Study) - Safety interim analysis results

Fischer L. von Weikersthal,W. L. Vervenne,P. J. Goebell,C. Eichelberg,W. Freier,M. De Santis,U. Zimmermann,M. M. E. M. M. Bos,L. Trojan, C. Lerchenmueller, M. Schenck,M. Staehler,

ONKOLOGIEno. SUPnan (2012): 237-237

引用5浏览0引用

EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from a randomized, cross-over AIO phase III trial

S. Boeck, A. Jung,R. P. Laubender,J. Neumann, R. Egg, C. Goritschan,U. Vehling-Kaiser, C. Winkelmann,Fischer L. von Weikersthal, M. R. Clemens, T. Gauler, A. Maerten,

ONKOLOGIEno. SUPnan (2011): 216-216

引用0浏览0引用

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn